Product information and disease descriptionProduct descriptionProduct informationDosing and administration
Dosage
6 evidence topics · 10 sources
Phase 3 regimens: 150 mg every 4 weeks after a 300 mg loading dose, or 300 mg every 8 weeks after a 450 mg loading dose
Dosing regimen named in the company summary of phase 3 data: every 4 weeks
Dose regimen proposed for licensure
No evidence found.
Phase 3b long-term extension retreatment regimen
| Group | Quoted arm description |
|---|---|
| Official title | “A Phase 3b Long-term Efficacy and Safety Extension Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria Who Have Completed CDX0159-12 or CDX0159-13” |
| Group 2 Barzolvolimab Retreatment Group | “Barzolvolimab given once as a 300 mg subcutaneous injection followed by 150 mg administered every 4 weeks for 52 weeks” |
| Group 1 Observation Group, worsening disease | “barzolvolimab will be administered once as a 300 mg subcutaneous injection followed by 150 mg every 4 weeks for up to 52 weeks.” |
Phase 2 regimens
| Arm | Quoted arm description |
|---|---|
| Barzolvolimab 75 mg then 150 mg | “barzolvolimab 75 mg injection subcutaneous every 4 weeks for 16 weeks and then 150 mg injection subcutaneous every 4 weeks for 36 weeks” |
| Barzolvolimab 75 mg then 300 mg | “barzolvolimab 75 mg injection subcutaneous every 4 weeks for 16 weeks and then 300 mg injection subcutaneous every 8 weeks for 36 weeks” |
| Barzolvolimab 150 mg | “barzolvolimab 150 mg injection subcutaneous every 4 weeks for 52 weeks” |
| Barzolvolimab 300 mg | “barzolvolimab 300 mg injection subcutaneous every 8 weeks for 52 weeks” |
| Placebo then barzolvolimab 150 mg | “Placebo injection subcutaneous every 4 weeks for 16 weeks and then barzolvolimab 150 mg injection subcutaneous every 4 weeks for 36 weeks” |
| Placebo then barzolvolimab 300 mg | “Placebo injection subcutaneous every 4 weeks for 16 weeks and then barzolvolimab 300 mg injection subcutaneous every 8 weeks for 36 weeks” |
Phase 1b intravenous regimens in mg/kg
“Phase 1b double‐blind placebo‐controlled trial (NCT04538794) in adults with moderate‐to‐severe (urticaria activity score over 7 days [UAS7] ≥ 16) antihistamine–refractory CSU treated with intravenous barzolvolimab for 12 weeks with a 12‐week follow‐up” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients were randomly assigned in a 4:1 ratio to receive a 60‐min intravenous infusion of either barzolvolimab or placebo (saline) Q4W or Q8W according to their assigned cohort (1: 0.5 mg/kg Q4W; 2: 1.5 mg/kg Q4W; 3: 3.0 mg/kg Q8W; and 4: 4.5 mg/kg Q8W) over 12 weeks as add‐on treatment to H1 antihistamine either alone or in combination with H2 antihistamine and/or LTRA (administered prior to study drug infusion).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote